Gold Investment Management Ltd. Buys 279 Shares of Johnson & Johnson $JNJ

Gold Investment Management Ltd. grew its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% in the second quarter, HoldingsChannel.com reports. The fund owned 18,790 shares of the company’s stock after acquiring an additional 279 shares during the period. Gold Investment Management Ltd.’s holdings in Johnson & Johnson were worth $2,914,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Naples Global Advisors LLC increased its stake in shares of Johnson & Johnson by 3.5% in the 2nd quarter. Naples Global Advisors LLC now owns 48,414 shares of the company’s stock valued at $7,395,000 after acquiring an additional 1,655 shares during the last quarter. Pure Financial Advisors LLC grew its position in shares of Johnson & Johnson by 40.9% in the 2nd quarter. Pure Financial Advisors LLC now owns 28,037 shares of the company’s stock valued at $4,283,000 after purchasing an additional 8,140 shares during the period. RKL Wealth Management LLC grew its position in shares of Johnson & Johnson by 0.5% in the 2nd quarter. RKL Wealth Management LLC now owns 27,808 shares of the company’s stock valued at $4,248,000 after purchasing an additional 128 shares during the period. Consolidated Planning Corp grew its position in shares of Johnson & Johnson by 19.7% in the 2nd quarter. Consolidated Planning Corp now owns 6,422 shares of the company’s stock valued at $981,000 after purchasing an additional 1,055 shares during the period. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of Johnson & Johnson by 1.4% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,805,207 shares of the company’s stock valued at $275,745,000 after purchasing an additional 25,183 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday. Citigroup boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Bank of America boosted their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $187.47.

Johnson & Johnson Trading Up 1.4%

NYSE:JNJ opened at $188.51 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $189.78. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average price of $176.18 and a two-hundred day moving average price of $162.83. The company has a market cap of $453.98 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.